Table 5.
Age | Gender | BMI (kg/m2) |
ASA class | Indication for ERCP | Procedure time (min) | Type and dose of sedative | Accompanying symptom | Treatment |
---|---|---|---|---|---|---|---|---|
84 | Female | 24.9 | III | CBD Stone | 6 |
Midazolam (5 mg) |
Agitation | Flumazenil |
84 | Male | 21.1 | I | CBD Stone | 32 |
Midazolam (10 mg) |
Agitation | Flumazenil |
88 | Female | 22.6 | II | CBD Stone | 6 |
Midazolam (10 mg) |
Bradycardia | Flumazenil |
92 | Female | 18.2 | I | CBD Stone | 27 |
Midazolam (5 mg) |
Tachycardia |
Flumazenil HFNO 0.7/50 |
89 | Male | 28.4 | II | CBD Stone | 25 |
Midazolam (5 mg) |
Agitation |
Flumazenil HFNO 0.6/50 |
79 | Female | 16.9 | II | CBD Stone | 12 |
Midazolam plus Propofol (5 mg plus 30 mg) |
Agitation |
Flumazenil HFNO 0.7/50 |
59 | Male | 26.6 | II | CBD Stone | 13 | Propofol (240 mg) | Agitation |
HFNO 0.7/50, Stop ERCP |
82 | Male | 18.7 | I | CBD Stone | 13 |
Midazolam (5 mg) |
Agitation |
Flumazenil HFNO 0.7/50 |
82 | Male | 18.5 | III | CBD Stone | 3 |
Midazolam (5 mg) |
Agitation |
Flumazenil HFNO 0.7/50 |
BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; CAOD, coronary artery obstructive disease; MI, myocardial infarction; CHF, congestive heart failure; ASA, the American Society of Anesthesiologists; CBD, common bile duct; HFNO, high flow nasal oxygen.